Literature DB >> 22722777

Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring.

Chao Zhang1, Paolo Denti, Jan-Stefan van der Walt, Yuan Ren, Peter Smith, Mats O Karlsson, Helen McIlleron.   

Abstract

BACKGROUND: Interpretation of antiretroviral drug concentration measurements could be aided by information about adherence to recent doses. We developed a population pharmacokinetic model of lamivudine in young children to propose reference lamivudine concentrations for evaluation of adherence to recent treatment doses.
METHODS: The steady state pharmacokinetics of lamivudine were evaluated in 68 young HIV-infected children receiving antiretroviral treatment twice daily. A population pharmacokinetic analysis was conducted using NONMEM 7.
RESULTS: A 2-compartment model with transit absorption best described lamivudine pharmacokinetics. After adjustment for maturation and body weight (using allometric scaling), the variability of clearance was small, hence simulations could accurately predict lamivudine concentrations. Higher lamivudine trough concentrations were detected before the morning dose, possibly owing to slower overnight clearance. Reference values for lamivudine concentrations that can be used to evaluate adherence to recent doses are proposed.
CONCLUSIONS: Lamivudine concentration measurement can be used to assess recent treatment adherence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22722777     DOI: 10.1097/FTD.0b013e31825c6067

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

Authors:  Esther J H Janssen; Diane E T Bastiaans; Pyry A J Välitalo; Annemarie M C van Rossum; Evelyne Jacqz-Aigrain; Hermione Lyall; Catherijne A J Knibbe; David M Burger
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

2.  Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.

Authors:  Chiara Piana; Wei Zhao; Kimberly Adkison; David Burger; Evelyne Jacqz-Aigrain; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

3.  Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.

Authors:  Sarah K Wendel; Caroline E Mullis; Susan H Eshleman; Joel N Blankson; Richard D Moore; Jeanne C Keruly; Ron Brookmeyer; Thomas C Quinn; Oliver Laeyendecker
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

4.  Adherence to metformin in adults with type 2 diabetes: a combined method approach.

Authors:  Nadia Farhanah Syafhan; Rosemary Donnelly; Roy Harper; Janet Harding; Ciara Mulligan; Anita Hogg; Michael Scott; Glenda Fleming; Claire Scullin; Ahmed F Hawwa; Gaoyun Chen; Carole Parsons; James C McElnay
Journal:  J Pharm Policy Pract       Date:  2022-10-12

5.  Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children.

Authors:  Junjie Ding; Matthew E Coldiron; Bachir Assao; Ousmane Guindo; Daniel Blessborn; Markus Winterberg; Rebecca F Grais; Alena Koscalova; Celine Langendorf; Joel Tarning
Journal:  Clin Pharmacol Ther       Date:  2019-12-31       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.